CA2478931A1 - A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus - Google Patents

A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus Download PDF

Info

Publication number
CA2478931A1
CA2478931A1 CA002478931A CA2478931A CA2478931A1 CA 2478931 A1 CA2478931 A1 CA 2478931A1 CA 002478931 A CA002478931 A CA 002478931A CA 2478931 A CA2478931 A CA 2478931A CA 2478931 A1 CA2478931 A1 CA 2478931A1
Authority
CA
Canada
Prior art keywords
phytostanol
group
insulin
phytosterol
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478931A
Other languages
English (en)
French (fr)
Inventor
Tatjana Lukic
Haydn P. Pritchard
Kishor M. Wasan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Forbes Medi-Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc filed Critical Forbes Medi-Tech Inc
Publication of CA2478931A1 publication Critical patent/CA2478931A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002478931A 2002-03-14 2003-03-14 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus Abandoned CA2478931A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9874502A 2002-03-14 2002-03-14
US10/098,745 2002-03-14
PCT/CA2003/000369 WO2003075931A1 (en) 2002-03-14 2003-03-14 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus

Publications (1)

Publication Number Publication Date
CA2478931A1 true CA2478931A1 (en) 2003-09-18

Family

ID=27804294

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478931A Abandoned CA2478931A1 (en) 2002-03-14 2003-03-14 A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus

Country Status (11)

Country Link
EP (1) EP1482950A1 (pt)
JP (1) JP2005528353A (pt)
KR (1) KR20040104513A (pt)
CN (1) CN1681514A (pt)
AU (1) AU2003218547B2 (pt)
BR (1) BR0308396A (pt)
CA (1) CA2478931A1 (pt)
NO (1) NO20044346L (pt)
NZ (1) NZ535200A (pt)
RU (1) RU2334518C2 (pt)
WO (1) WO2003075931A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
AU2010298733B2 (en) * 2009-09-28 2014-10-09 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
AU2016314373A1 (en) * 2015-09-03 2018-03-29 Natural Shield Israel 2016 Ltd Combined compositions for controlling blood sugar levels, hepatoprotection, and for prevention and treatment of related medical conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000653A1 (en) * 1999-06-23 2001-01-04 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease

Also Published As

Publication number Publication date
AU2003218547B2 (en) 2007-11-01
NZ535200A (en) 2007-07-27
BR0308396A (pt) 2005-01-11
RU2334518C2 (ru) 2008-09-27
AU2003218547A1 (en) 2003-09-22
NO20044346L (no) 2004-12-09
RU2004130463A (ru) 2005-04-10
KR20040104513A (ko) 2004-12-10
EP1482950A1 (en) 2004-12-08
CN1681514A (zh) 2005-10-12
JP2005528353A (ja) 2005-09-22
WO2003075931A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
EP1227734B1 (en) Compositions comprising edible oils or fats and phytosterols and/or phytostanols dissolved therein
US8071558B2 (en) Application of D-psicose to suppression of abnormal circadian increase in blood glucose level
US20020156051A1 (en) Novel structures comprising phytosterol and/or phytostanol and ascorbic acid and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
US20030203854A1 (en) Composition for effecting serum cholesterol levels
AU2003218547B2 (en) A method of treating diabetes mellitus including conditions associated with diabetes mellitus and complications of diabetes mellitus
US9642875B2 (en) Compounds and their effects on appetite control and insulin sensitivity
JP2008222656A (ja) 肥満改善および予防用組成物ならびに健康食品
WO2001066560A2 (en) Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
EP1644007B1 (en) Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes
US20100286104A1 (en) Agent for inhibiting visceral fat accumulation
JP2001278804A (ja) 脂質代謝改善剤及びそれを含有する食品
KR100886466B1 (ko) 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물
WO2004014159A1 (en) Method of lowering glycaemic index of foods
EP1333838B1 (en) Compounds comprising a phytosterol and/or phytostanol moiety and ascorbic acid and use thereof as weight regulating agents
EP1250350B1 (en) Novel crystalline composites comprising phytosterols and phytostanols or derivatives thereof
CN115038435A (zh) 肥胖抑制用组合物
JP6770726B1 (ja) メタボリックシンドロームの予防または改善剤
JPH0410448B2 (pt)
DE60218165T2 (de) Lipolyseförderer zur Reduzierung des Körpergewichts und medizinische Anwendung
AU2007203095A1 (en) Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents
CA2461136A1 (en) A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl)
KR20040017891A (ko) 레반을 이용한 비만 개선 식이 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued